Skip to content

STAT Trial: Stoma or Intestinal Anastomosis for Necrotizing Enterocolitis of the Neonate: Multicentre Randomized Controlled Trial

STAT Trial: Stoma or Intestinal Anastomosis for Necrotizing Enterocolitis of the Neonate: Multicentre Randomized Controlled Trial - STAT trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON34083
Enrollment
10
Registered
2010-09-06
Start date
2011-02-21
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

necrotizing enterocolitis

Interventions

Anastomosis or stoma formation after bowel resection

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
2 Years to 11 Years

Inclusion criteria

Inclusion criteria: 1. Suspected NEC 2. Need for laparotomy based on: 2.1. Radiological signs of intestinal perforation or 2.2. Failure of improvement with medical treatment 3. Aged 0 - 6 months, either sex

Exclusion criteria

Exclusion criteria: 1. No evidence of NEC (e.g. intestinal volvulus) 2. Focal intestinal perforation (since many surgeons would not perform a stoma) 3. Extensive NEC precluding intestinal anastomosis (intestinal resection will result in short bowel) 4. NEC affecting the colon that cannot be completely assessed because of risk of bleeding 5. Patient's instability during the operation

Design outcomes

Primary

MeasureTime frame
The primary end point of the study will be duration of parenteral nutrition (days), as this reflects the recovery of intestinal function after NEC and will be affected by complications and/or need for further procedures.

Secondary

MeasureTime frame
The secondary end points of the study will be: 1. mortality at 1, 3 and 6 months after randomization. 2. number and type of surgical procedures performed (including insertion of central venous lines); 3. hospital stay (days) for survivors and non survivors; 4. intestinal absorptive function. This will be assessed by measuring: i) calorie intake (kcal/kg/day) both enterally and parenterally 1 month and 6 months after randomization; ii) weight gain at 1 month and 6 months after randomization; iii) time (days) to full enteral feeding; iv) requirement for medication to slow intestinal transit time. 5. intestinal complications: a) stricture (of either anastomosis or remaining intestine, confirmed by a contrast study and/or histology); b) anastomotic leak; c) prolapse of stoma; d) stoma necrosis; e) intestinal obstruction; f) high output stoma; g) recurrence of NEC; 6. wound complication (infection, incisional hernia, dehiscence); 7. days on antibiotics, incidence of sepsis (positive blood culture), intraabdominal abscess requiring drainage or reoperation; 8. intraventricular haemorrhage (ultrasound scan of the brain at enrolment in the trial and 2 weeks after randomization); intraventricular haemorrhages will be graded (grade I to IV) according to their extent and severity. 9. respiratory function. This will be assessed by recording the need for assisted ventilation or oxygen dependency at 1 and 6 months after randomization. 10. cost of hospital treatment 11. time to death (days); 12. cause of death (related to abdominal sepsis/not related to abdomen [cardiac anomaly/cerebral haemorrhage/other]).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)